News
Watch
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Thomas C. Fenter, MD

Articles by Thomas C. Fenter, MD

Dutasteride vs Finasteride: Assessment of Differences in Acute Urinary Retention Rates and Surgical Risk Outcomes in an Elderly Population Aged ≥65 Years

ByThomas C. Fenter, MD,E. Anne Davis, PharmD, MS,Manan B. Shah, PharmD, PhD,Pei-Jung Lin, PhD

May 1st 2008

Finasteride Versus Dutasteride: A Real-world Economic Evaluation

ByThomas C. Fenter, MD,M. Chris Runken, PharmD,Libby Black, PharmD,Michael Eaddy, PharmD, PhD

February 1st 2007

An Assessment of the Diagnosed Prevalence of Diseases in Men 50 Years of Age or Older

ByMuta M. Issa, MD, MBA,Thomas C. Fenter, MD,Libby Black, PharmD,Amy L. Grogg, PharmD,Eric J. Kruep, PharmD, MS

March 1st 2006

The Cost of Treating the 10 Most Prevalent Diseases in Men 50 Years of Age and Older

ByThomas C. Fenter, MD,Michael James Naslund, MD, MBA,Manan B. Shah, PharmD, PhD,Michael T. Eaddy, PharmD, PhD,Libby Black, PharmD

March 1st 2006

Latest Updated Articles

Trending on AJMC

COPD Deaths Rival Heart Failure, Exceed Prostate and Breast Cancer

AI Model Flags Colorectal Cancer on Routine Noncontrast CT Scans

FDA Approves Camizestrant for ER+, HER2– mBC With ESR1 Mutations

Vutrisiran Effects Consistent With, Without Tafamidis in ATTR-CM

CKM Guideline Aims to Break Down Specialty Silos: Keith Bellovich, DO